Browsing Tag
VP-315
2 posts
Could intratumoral peptide immunotherapy alter first-line thinking in basal cell carcinoma?
Could VP-315 reshape first-line basal cell carcinoma treatment? Read the executive analysis on strategy, competition, and commercial risks.
Verrica’s SITC reveal: can VP-315’s immune activation data reshape the skin cancer treatment landscape
Find out how Verrica’s VP-315 immune activation data at SITC 2025 could redefine non-surgical skin cancer treatment options for dermatologic oncology.